Intercept Pharmaceuticals (ICPT) PT Trimmed to $140 at Leerink Partners

Intercept Pharma (ICPT):Higher-Than-Anticipated Pricing Could Set the Stage for a Slow Ocaliva Launch - FBR

FBR Capital analyst, Vernon Bernardino, maintained his Market Perform rating on Intercept Pharmaceuticals (NASDAQ: ICPT) and believes "that the upside potential and downside risk are evenly balanced" as higher-than-anticipated pricing could pose a high hurdle for gaining medical insurance (payor) coverage. PT increases to $200 (from... More

Wedbush Updates PT on Intercept Pharma (ICPT) Following OCALIVA Approval for PBC; Affirms at 'Outperform'

Wedbush is updating its price target on Outperform-rated Intercept Pharma (Nasdaq: ICPT) from $423 to $239.

Analyst Liana Moussatos commented, Intercept announced U.S. approval of obeticholic acid (OCA) as OCALIVA for primary biliary cholangitis (PBC). Although management guided to an initial gradual... More

Intercept Pharmaceuticals (ICPT) PT Comes Down to $239 at Wedbush Following OCALIVA Approval

Wedbush analyst Liana Moussatos reiterated an Outperform on Intercept Pharmaceuticals (NASDAQ: ICPT) while converting to a 12-month price target of $239.00 (from acquisition value of $423.00) after the company anounced U.S. approval of obeticholic acid (OCA) as OCALIVA for primary biliary cholangitis (PBC).

While... More

Intercept (ICP) OCA Approval a 'Major De-Risking Event' - BMO

BMO Capital analyst M. Ian Somaiya reiterated an Outperform Intercept Pharmaceuticals (NASDAQ: ICPT) but trimmed its price target to $219.00 (from $221.00) following Ocaliva approval.

Somaiya commented, "We believe Ocalivas approval in primarily biliary cholangitis (PBC) is a major de-risking event for ICPT. We... More

Intercept (ICPT) Most Lucrative Opportunity Remains in NASH - Baird

Baird analyst Brian Skorney reiterated an Outperform rating and $332 price target on Intercept Pharmaceuticals (NASDAQ: ICPT) after the FDA, as expected, approved Intercept's obeticholic acid, branded as Ocaliva, for the drug's first indication, primary biliary cholangitis (PBC).

"Though this does signal Intercept's transition... More

Needham & Company Positive on Intercept Pharma (ICPT); Expects Initial Ocaliva Uptake to be 'Strong'

Needham & Company affirms Intercept Pharma (Nasdaq: ICPT) at Buy with a price target of $350 after the company received FDA... More

Intercept Pharma (ICPT) says Ocaliva list price is $69,350/year

Intercept Pharma (NASDAQ: ICPT) says Ocaliva list price is $69,350/year

Intercept Pharma (ICPT) Granted Accelerated FDA Approval of Ocaliva in PBC

Late Friday, Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT) announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Ocaliva (obeticholic acid) for the treatment of primary biliary cholangitis, previously known as primary biliary cirrhosis (PBC), in combination with ursodeoxycholic (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. Ocaliva is an agonist of the farnesoid X receptor (FXR), a nuclear receptor expressed in the liver and intestine and a key regulator of bile acid, inflammatory, fibrotic... More